Mohammed T Qatanani

This inventor holds 61 USPTO granted patents and 51 published patent applications, primarily in Muscle Targeting Complexes. Top assignees: Dyne Therapeutics, Inc., Hercules Capital, Inc., as Agent. Active years: 2021-2026.

USPTO Granted Patents = 61 (Patent Applications = 51)

% Patents Active = 100.0

Average Co-Inventor Count = 4.2

ph-index = 23

Forward Citations = 1,132(Granted Patents)

Forward Citations (Not Self Cited) = 25(Dec 10, 2025)

Company Filing History:

59 out of 59

Dyne Therapeutics, Inc.

patents

2 out of 6

Hercules Capital, Inc., as Agent

patents

Years Active: 2021-2026

Loading Chart...

Areas of Expertise:

Muscle Targeting

Dystrophinopathies

Myotonic Dystrophy

Anti-Transferrin Receptor Antibody

Oligonucleotide Delivery

Exon Skipping

Duchenne Muscular Dystrophy

Facioscapulohumeral Muscular Dystrophy

Complex Formulations

Therapeutic Applications

Gene Therapy

Muscle Weakness

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12746290 - MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY (2026-09-29),

2. 12742007 - MUSCLE-TARGETING COMPLEXES AND USES THEREOF (2026-09-22),

3. 12734246 - ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY, ENCODING NUCLEIC ACID THEREOF AND METHOD OF USE THEREOF TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT (2026-09-15),

4. 12697394 - MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY (2026-08-04),

5. 12662545 - Complexes Comprising An Anti-Transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering Oligonucleotide To A Subject (2026-06-23),

6. 12629426 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2026-05-19),

7. 12624120 - ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF (2026-05-12),

8. 12496352 - MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY (2025-12-16),

9. 12478687 - MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO TREAT DUCHENNE MUSCULAR DYSTROPHY (2025-11-25),

10. 12460011 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject (2025-11-04),

11. 12440575 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-10-14),

12. 12440574 - Muscle targeting complexes and formulations for treating myotonic dystrophy (2025-10-14),

13. 12428487 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject (2025-09-30),

14. 12403203 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-09-02),

15. 12397062 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-08-26),

Title: The Innovative Journey of Mohammed T Qatanani

Introduction: Mohammed T Qatanani is a pioneering inventor based in Waltham, MA (US) known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Mohammed T Qatanani holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Mohammed T Qatanani has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Mohammed T Qatanani has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Mohammed T Qatanani's relentless pursuit of innovation and his passion for creating solutions that make a difference have solidified his reputation as a visionary inventor in the field of technology.